INAB

IN8bio, Inc. (INAB) | Rumor.io

IN8bio

INAB

Attention (50-day avg)0%

Attention rank (50-day avg)#3,655

Bullish sentiment (50-day avg)60%

Price to earnings ratio-0.28

Market capitalization12.2M

Earnings per share-1.3

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-19.4M

Social

What share of all stock conversation is about INAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Dec 22

IN8bio, Inc. ($INAB) has a strong potential for growth due to its preclinical and clinical results, with a market capitalization of $6.4 million.
The company's INB-200 and INB-400 candidates are being developed to treat glioblastoma, a type of brain cancer, and may have a synergistic effect with Temodar, a chemotherapy drug.
IN8bio's approach, called Drug Resistant Immunotherapy (DRI), allows chemotherapy and immunotherapy to be administered simultaneously, creating a combined attack on cancer cells.

Generated by AI

Sentiment

Of the messages about INAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +44.44	92.23% +9.82
Bearish	—	—	0% -44.44	7.77% -9.82

Bullish· Dec 19

IN8bio's private placement of up to $40.2 million is expected to result in a 5X-10X increase in the stock price over the next 12-18 months.
The company's cash runway has been extended into H1 2027, providing a significant boost to its financial position.
IN8bio's advanced pre-clinical and pipeline make it a promising investment opportunity, especially considering its low market capitalization of less than $50 million.

Bearish· Jun 2

The market may respond negatively to news about IN8bio, Inc. ($INAB), potentially leading to a price drop.
Institutional investors may be pushing the stock down to buy it cheaper, as they often do in penny bio stocks.
The company's executives have been collecting millions of dollars per year for the past five years, raising concerns about the company's performance and potential for further losses.

Generated by AI

Topics

Of the messages about INAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	88.4%
Technical Analysis	—	0%	0%	11.05%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.55%
Macro	—	0%	0%	0%

Announcements· Dec 19

IN8bio, Inc. (INAB) has priced a private placement of up to $40.2 million to advance its novel gamma-delta T cell engager, INB-619, through an Investigational New Drug (IND) application.
The initial tranche of $20.1 million will fund operations through the first half of 2027, with additional funds of up to $20.1 million available upon satisfaction of certain conditions related to INB-619's preclinical data and share price.
The private placement will support the IND-enabling studies for INB-619, the advancement of the INB-200 and INB-400 glioblastoma programs, interactions with the FDA, and general corporate purposes.

Technical Analysis· Feb 11

IN8bio, Inc. ($INAB) has broken back above intraday support, with a next key break at $0.34 potentially leading to a big move.
The stock's price is not matching the news, with bears likely to become overextended, and a target of $0.75 and $1.00 being set for price discovery.
IN8bio, Inc. ($INAB) is struggling to break above the 50-day moving average (MA50), with a failure to do so potentially leading to a decline.

Generated by AI

Community

Of the messages about INAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	50%	72.73%	50.49%
Newcomers	—	50%	27.27%	49.51%

Regulars· Feb 11

IN8bio reports updated positive results from the Phase 1 Trial of INB-100 in Leukemia patients, with 100% of AML patients maintaining complete remission and several patients maintaining remission for over three years.
The company's updated positive results from the Phase 1 Trial of INB-100 in Leukemia patients include a median follow-up of 20.1 months, with several patients maintaining remission for over three years.
IN8bio's INB-100 has demonstrated prolonged remissions supported by gamma-delta T cells, with patients treated showing one-year progression-free.

Newcomers· Dec 19

IN8bio, Inc. (INAB) announced a private placement of up to $40.2 million to fund the development of a new gamma-delta T cell engager, a type of immunotherapy for cancer and autoimmune diseases.
The company's shares are trading higher after the announcement, with some analysts expecting a positive impact on the company's clinical-stage gamma-delta T-cell therapies.
IN8bio's focus on gamma-delta T cell therapies has raised questions among biotech investors, with some speculating about the potential of this new approach to treat cancer and autoimmune diseases.

Generated by AI

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026. Mr. Ho will participate in one-on-one meetings with investors throughout the conference and deliver a company

7d agoYahoo Finance

IN8bio at H.C. Wainwright conference: gamma delta bets gain traction

15d agoInvesting.com

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

20d agoYahoo Finance

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 4,000 shares of its common stock. The award was approved by the Compensation Committee of the C

1mo agoYahoo Finance

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half of 2026Presented updated data at ASCO 2026 demonstrating median overall survival (mOS) exceeding 19.5 months and still climbing, across all patients with newly diagnosed glioblastoma (GBM) treated with repeat-dosing of DeltEx™ Drug Resistant Immunotherapy (DRI)P

1mo agoYahoo Finance

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

2mo agoYahoo Finance

Also Discussed

Investors talking about INAB also mention

#	Name	Attention
1	Ocean Biomedical Inc.OCEA	0%0
2	Shattuck Labs, Inc.STTK	0%new
3	LVTX - LAVA Therapeutics N.V.	——
4	C4 Therapeutics IncCCCC	0%new
5	AGM Group Holdings IncAGMH	0%0
6	Biodesix, Inc.BDSX	0%0
7	Lyell Immunopharma, Inc.LYEL	0.01%new
8	Agape Atp CorpATPC	0%0
9	HHRS - Hammerhead Energy Inc.	——
10	PBY - Prospect Capital Corporation	——

IN8bio, Inc.

Healthcare
Biotechnology

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases. IN8bio’s current pipeline centers on cell-based immunotherapies designed to target solid and hematologic tumors, with programs spanning allogeneic, autologous, iPSC-derived, and genetically modified approaches. Its lead and clinical programs include candidates being studied in glioblastoma and leukemia settings, reflecting the company’s emphasis on difficult-to-treat cancers and unmet medical needs. IN8bio also advances a T cell engager platform intended to broaden the reach of its immunotherapy portfolio across oncology and autoimmune indications. Based in New York, IN8bio plays a niche role in the biotechnology market as a developer of next-generation cellular medicines.

Website

Location

350 5th Avenue

New York, NY, 10118

United States

Social

What share of all stock conversation is about INAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Dec 22

IN8bio, Inc. ($INAB) has a strong potential for growth due to its preclinical and clinical results, with a market capitalization of $6.4 million.
The company's INB-200 and INB-400 candidates are being developed to treat glioblastoma, a type of brain cancer, and may have a synergistic effect with Temodar, a chemotherapy drug.
IN8bio's approach, called Drug Resistant Immunotherapy (DRI), allows chemotherapy and immunotherapy to be administered simultaneously, creating a combined attack on cancer cells.

Generated by AI

Sentiment

Of the messages about INAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +44.44	92.23% +9.82
Bearish	—	—	0% -44.44	7.77% -9.82

Bullish· Dec 19

IN8bio's private placement of up to $40.2 million is expected to result in a 5X-10X increase in the stock price over the next 12-18 months.
The company's cash runway has been extended into H1 2027, providing a significant boost to its financial position.
IN8bio's advanced pre-clinical and pipeline make it a promising investment opportunity, especially considering its low market capitalization of less than $50 million.

Bearish· Jun 2

The market may respond negatively to news about IN8bio, Inc. ($INAB), potentially leading to a price drop.
Institutional investors may be pushing the stock down to buy it cheaper, as they often do in penny bio stocks.
The company's executives have been collecting millions of dollars per year for the past five years, raising concerns about the company's performance and potential for further losses.

Generated by AI

Topics

Of the messages about INAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	88.4%
Technical Analysis	—	0%	0%	11.05%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.55%
Macro	—	0%	0%	0%

Announcements· Dec 19

IN8bio, Inc. (INAB) has priced a private placement of up to $40.2 million to advance its novel gamma-delta T cell engager, INB-619, through an Investigational New Drug (IND) application.
The initial tranche of $20.1 million will fund operations through the first half of 2027, with additional funds of up to $20.1 million available upon satisfaction of certain conditions related to INB-619's preclinical data and share price.
The private placement will support the IND-enabling studies for INB-619, the advancement of the INB-200 and INB-400 glioblastoma programs, interactions with the FDA, and general corporate purposes.

Technical Analysis· Feb 11

IN8bio, Inc. ($INAB) has broken back above intraday support, with a next key break at $0.34 potentially leading to a big move.
The stock's price is not matching the news, with bears likely to become overextended, and a target of $0.75 and $1.00 being set for price discovery.
IN8bio, Inc. ($INAB) is struggling to break above the 50-day moving average (MA50), with a failure to do so potentially leading to a decline.

Generated by AI

Community

Of the messages about INAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	50%	72.73%	50.49%
Newcomers	—	50%	27.27%	49.51%

Regulars· Feb 11

IN8bio reports updated positive results from the Phase 1 Trial of INB-100 in Leukemia patients, with 100% of AML patients maintaining complete remission and several patients maintaining remission for over three years.
The company's updated positive results from the Phase 1 Trial of INB-100 in Leukemia patients include a median follow-up of 20.1 months, with several patients maintaining remission for over three years.
IN8bio's INB-100 has demonstrated prolonged remissions supported by gamma-delta T cells, with patients treated showing one-year progression-free.

Newcomers· Dec 19

IN8bio, Inc. (INAB) announced a private placement of up to $40.2 million to fund the development of a new gamma-delta T cell engager, a type of immunotherapy for cancer and autoimmune diseases.
The company's shares are trading higher after the announcement, with some analysts expecting a positive impact on the company's clinical-stage gamma-delta T-cell therapies.
IN8bio's focus on gamma-delta T cell therapies has raised questions among biotech investors, with some speculating about the potential of this new approach to treat cancer and autoimmune diseases.

Generated by AI

IN8bio

Social

Dec 22

Bullish· Dec 19

Bearish· Jun 2

Announcements· Dec 19

Technical Analysis· Feb 11

Regulars· Feb 11

Newcomers· Dec 19

IN8bio to Present at Sidoti Small-Cap Virtual Conference

IN8bio at H.C. Wainwright conference: gamma delta bets gain traction

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

Also Discussed

IN8bio, Inc.

Company Information

Location

IN8bio to Present at Sidoti Small-Cap Virtual Conference

IN8bio at H.C. Wainwright conference: gamma delta bets gain traction

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

Also Discussed

Social

Dec 22

Bullish· Dec 19

Bearish· Jun 2

Announcements· Dec 19

Technical Analysis· Feb 11

Regulars· Feb 11

Newcomers· Dec 19